GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL GLIOBLASTOMA PRE-CLINICAL RESULTS
For Immediate Release Contact: info@globalcancertechnology.com GCT-007 CONTINUES TO RECEIVE EXCEPTIONAL
CHINA ISSUES GLOBAL CANCER TECHNOLOGY PATENT FOR GCT-007
For Immediate Release Contact: info@globalcancertechnology.com CHINA ISSUES GLOBAL CANCER TECHNOLOGY
DATA SHOWS GCT-007 TO BE COMPARABLE TO PAXALISIB IN INITIAL PRE-CLINICAL STUDIES
For Immediate Release Contact: info@globalcancertechnology.com GLOBAL CANCER TECHNOLOGY REPORTS
GLOBAL CANCER TECHNOLOGY RECIEVES EURASIAN GRANT OF LICENSED PATENT
For Immediate Release Contact: info@globalcancertechnology.com GLOBAL CANCER TECHNOLOGY
GLOBAL CANCER TECHNOLOGY EXHIBITS AT THE ‘KUKUNA O KA LA’ RADIATION ONCLOGY CONFERENCE IN KONA
Global Cancer Technology is innovating the treatment of deadly diseases like glioblastoma – it’s not science fiction any more! Scintillating nanoparticles can theoretically be coated in GCT’s cancer inhibitor that is currently being tested in animal models, then be injected into the bloodstream and designed to bind to the tumor’s surface.
